What Led to the Drop in Calidi Biotherapeutics Stock?
Calidi Biotherapeutics Inc (NASDAQ: CLDI) has recently experienced a 13.3% decline in its stock price, trading at approximately 98 cents. This downturn comes after the company disclosed a securities purchase agreement involving institutional investors. They plan to sell 2,050,000 shares of common stock at a price of $1.00 per share as part of a registered direct offering.
Details of the Securities Purchase Agreement
In conjunction with the sale of common stock, Calidi Biotherapeutics is engaging in a concurrent private placement where it will issue series E and F warrants. These warrants will enable investors to buy an additional 2,050,000 shares at a slightly higher price of $1.13 per share. This structured approach illustrates the company's strategy to raise capital while providing investment opportunities.
Understanding the Series E and F Warrants
The series E warrants will be exercisable six months following their issuance, essentially giving early access to the shares. They come with a one-year term, while the series F warrants offer a longer five-year term. Such stipulations can be appealing to investors looking for long-term investment options.
Anticipated Closure of the Transaction
The transactions associated with the sale are set to close shortly, specifically around a date near the end of October. Ladenburg Thalmann & Co. will serve as the exclusive placement agent, which adds a layer of professionalism and market insight to the process.
Investment Opportunities with CLDI Stock
If you are interested in acquiring shares of Calidi Biotherapeutics, there are various methods to consider. One straightforward way is to purchase through a brokerage platform, whether it be a full share or a fractional share of the stock.
Exploring ETF Investments
Alternatively, you can invest in exchange-traded funds (ETFs) that include Calidi Biotherapeutics shares within their portfolios. These financial products allow you to diversify your investments, thus managing risk while gaining exposure to the health care sector.
Market Performance Overview
The current market landscape for Calidi Biotherapeutics shows that the stock has fluctuated significantly over the past year, recording a 52-week high of $29.30 and a low of $0.96. These figures highlight the volatility within the stock and the potential risks involved.
Frequently Asked Questions
Why did Calidi Biotherapeutics stock drop recently?
The stock fell due to an announcement regarding a securities purchase agreement and subsequent share issuance.
What are series E and F warrants?
These are financial instruments that allow investors to purchase shares at a predetermined price within a specified time frame.
When will the transaction involving Calidi Biotherapeutics close?
The deals are expected to close around the end of October.
How can I invest in Calidi Biotherapeutics?
You can invest through a brokerage or consider ETFs that hold CLDI stock.
What were the stock's 52-week high and low prices?
The stock recorded a high of $29.30 and a low of $0.96 in the past year.
